Wan Jovian, Kim Soo-Bin, Cartier Hugues, Garson Sebastien, Frank Konstantin, Haykal Diala, Yi Kyu-Ho
Medical Research Inc., Wonju, Republic of Korea.
Department of Oral Anatomy, College of Dentistry, Wonkwang University, Iksan, 54538, Republic of Korea.
Aesthetic Plast Surg. 2025 Mar 27. doi: 10.1007/s00266-025-04817-9.
Androgenetic alopecia (AGA) is a prevalent condition that significantly impacts patients' psychological well-being and quality of life. Traditional treatments, such as minoxidil and finasteride, have limited efficacy and undesirable side effects. Exosome therapy, which uses extracellular vesicles to promote tissue regeneration, offers a promising alternative. This study evaluates the effectiveness of exosome therapy combined with microneedling (MTS) for treating AGA.
To assess the efficacy of exosome therapy in promoting hair regrowth in patients with AGA following microneedling treatment.
This prospective, open-label study included 16 male patients aged 36-45 years with mild to moderate AGA. Microneedling was performed on the scalp followed by the application of exosome topical therapy (ZISHEL XOMAGE, Zishel Bio Inc., Seoul, Republic of Korea). Hair density and patient satisfaction were evaluated through clinical assessments and photographic documentation at 1, 3, 6, and 12 months after treatment. Side effects were also monitored.
At the 12-month follow-up, the average increase in hair density was 35 hairs/cm, with a standard deviation of 6.5 hairs/cm. Baseline hair densities ranged from 75 hairs/cm to 95 hairs/cm, with improvements observed in all patients. Patient satisfaction was high, with 80% of participants reporting noticeable improvements in hair regrowth and 87% indicating satisfaction or high satisfaction with the results. Mild side effects, including scalp tenderness and slight irritation, were reported but resolved within 48 hours.
Exosome therapy, in combination with microneedling, offers a promising non-surgical treatment for AGA, demonstrating significant improvements in hair regrowth and patient satisfaction. Further studies with larger samples and longer follow-up periods are needed to confirm the long-term efficacy of this approach.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors https://www.springer.com/00266 .
雄激素性脱发（AGA）是一种常见病症，会对患者的心理健康和生活质量产生重大影响。传统治疗方法，如米诺地尔和非那雄胺，疗效有限且存在不良副作用。外泌体疗法利用细胞外囊泡促进组织再生，提供了一种有前景的替代方案。本研究评估外泌体疗法联合微针疗法（MTS）治疗AGA的有效性。
评估外泌体疗法在微针治疗后促进AGA患者头发生长的疗效。
这项前瞻性、开放标签研究纳入了16名年龄在36 - 45岁的男性AGA患者，病情为轻度至中度。先在头皮上进行微针治疗，然后应用外泌体局部疗法（ZISHEL XOMAGE，韩国首尔Zishel生物公司）。在治疗后1、3、6和12个月通过临床评估和照片记录评估头发密度和患者满意度。同时监测副作用。
在12个月的随访中，头发密度平均增加了35根/平方厘米，标准差为6.5根/平方厘米。基线头发密度范围为75根/平方厘米至95根/平方厘米，所有患者均有改善。患者满意度较高，80%的参与者报告头发生长有明显改善，87%的参与者对结果表示满意或高度满意。报告了轻微的副作用，包括头皮压痛和轻微刺激，但在48小时内消退。
外泌体疗法联合微针疗法为AGA提供了一种有前景的非手术治疗方法，在促进头发生长和患者满意度方面有显著改善。需要进行更大样本量和更长随访期的进一步研究来证实这种方法的长期疗效。
证据等级IV：本期刊要求作者为每篇文章指定证据等级。有关这些循证医学评级的完整描述，请参阅目录或在线作者指南https://www.springer.com/00266 。
